A randomized double-masked controlled trial of dupilumab ver…

A randomized double-masked controlled trial of dupilumab versus benralizumab for patients with eosinophilic asthma was conducted. The study found dupilumab lowered the risk of severe asthma exacerbations more than benralizumab and calculated a number needed to treat of 87. What is the interpretation of the number needed to treat in the context of this scenario?